| Identification | Back Directory | [Name]
ADH-503 | [CAS]
2055362-74-6 | [Synonyms]
ADH503
ADH-503
ADH 503
ADH-503;ADH503;ADH 503
ADH-503 - Leukadherin-1 choline salt | [Molecular Formula]
C27H29N2O5S2+ | [MOL File]
2055362-74-6.mol | [Molecular Weight]
525.66 |
| Hazard Information | Back Directory | [Uses]
ADH-503 ((Z)-Leukadherin-1 choline) is an orally active and allosteric CD11b agonist. ADH-503 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses[1]. | [in vivo]
ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival[1].
ADH-503 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively[1].
| Animal Model: | KPC mice [p48-CRE/Lox-stop-Lox(LSL)-KrasG12D/p53flox/flox][1] | | Dosage: | 30, 60, or 120 mg/kg | | Administration: | Oral gavage; 60 days | | Result: | Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
|
| Animal Model: | Male rats[1] | | Dosage: | 30, 100 mg/kg (Pharmacokinetic Analysis) | | Administration: | Oral gavage twice a day; on days 1 and 5 | | Result: | Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC0-t in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively.
|
| [storage]
Store at -20°C | [References]
[1] Panni RZ, et al. Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies. Sci Transl Med. 2019 Jul 3;11(499). DOI:10.1126/scitranslmed.aau9240 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|